肠道微生物代谢5-氨基水杨酸降低其在炎症性肠病中的临床疗效
研究通过多组学流程分析IBDMDB队列132名对照和炎症性肠病患者的肠道微生物,鉴定出12种可乙酰化灭活5-氨基水杨酸的微生物乙酰转移酶,并在SPARC IBD队列(n=208)中验证其中4种酶与5-氨基水杨酸治疗失败风险升高相关。
要点
- 鉴定出12种属于硫解酶和酰基辅酶A N-乙酰转移酶超家族的微生物乙酰转移酶与5-氨基水杨酸灭活相关。
- 体外实验证实两个家族的代表性酶能够乙酰化5-氨基水杨酸。
- 在SPARC IBD队列中,3种微生物硫解酶和1种酰基辅酶A N-乙酰转移酶与5-氨基水杨酸使用者治疗失败风险升高存在流行病学关联。
核心结论
- 这些数据解决了炎症性肠病管理中的一个长期难题,提出了发现未知肠道微生物活性的方法,并推进了基于微生物组的个性化医疗的可能性。
研究设计与样本
- 研究开发了结合肠道微生物组宏基因组学、宏转录组学和代谢组学的多组学流程,分析纵向IBDMDB队列中132名对照和炎症性肠病患者。
- 在发现队列中进行横断面分析,并在独立的SPARC IBD队列(n=208)中进行前瞻性验证。
主要发现
- 将12种先前未表征的微生物乙酰转移酶与5-氨基水杨酸灭活相关联,这些酶属于两个蛋白超家族:硫解酶和酰基辅酶A N-乙酰转移酶。
- 体外表征两个家族的代表性酶证实了它们乙酰化5-氨基水杨酸的能力。
- 在发现队列的横断面分析和SPARC IBD队列(n=208)的前瞻性验证中,发现3种微生物硫解酶和1种酰基辅酶A N-乙酰转移酶与5-氨基水杨酸使用者治疗失败风险升高存在流行病学关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For decades, variability in clinical efficacy of the widely used inflammatory bowel disease (IBD) drug 5-aminosalicylic acid (5-ASA) has been attributed, in part, to its acetylation and inactivation by gut microbes. Identification of the responsible microbes and enzyme(s), however, has proved elusive. To uncover the source of this metabolism, we developed a multi-omics workflow combining gut microbiome metagenomics, metatranscriptomics and metabolomics from the longitudinal IBDMDB cohort of 132 controls and patients with IBD. This associated 12 previously uncharacterized microbial acetyltransferases with 5-ASA inactivation, belonging to two protein superfamilies: thiolases and acyl-CoA N-acyltransferases. In vitro characterization of representatives from both families confirmed the ability of these enzymes to acetylate 5-ASA. A cross-sectional analysis within the discovery cohort and subsequent prospective validation within the independent SPARC IBD cohort (n = 208) found three of these microbial thiolases and one acyl-CoA N-acyltransferase to be epidemiologically associated with an increased risk of treatment failure among 5-ASA users. Together, these data address a longstanding challenge in IBD management, outline a method for the discovery of previously uncharacterized gut microbial activities and advance the possibility of microbiome-based personalized medicine.
引用
- Mehta RS, Mayers JR, Zhang Y, et al. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. Nat Med. 2023. PMID: 36823301. doi:10.1038/s41591-023-02217-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。